Infection category
|
|
Severe invasive |
|
Sepsis |
A40.0, A40.1, A41 |
Meningitis |
A17.0, A17.8, A32.1, A85.1, A86, A87, B00.3, B00.4, B01.0, G01, G00.3, G00.8, G00.9, G02.0, G02.1, G03, G04 |
Septic arthritis |
M00, M46.5 |
Osteomyelitis |
M86 |
Pyelonephritis |
N10, N16.0 |
Cellulitis |
L03 |
Respiratory |
|
Bronchiolitis |
J21.0, J21.1, J21.8, J21.9 |
Influenza |
J10, J11 |
Croup |
J05, J20.9 |
Pneumonia |
J12.0, J12.2, J12.8, J12.9, J13, J14, J15.0, J15.1, J15.2, J15.4, J15.5, J15.6, J15.7, J15.8, J15.9, J16.0, J17, J18, P23 |
Viral wheeze |
R06.2 |
Upper respiratory tract infection |
J06 |
Otitis media |
H65, H66, H67 |
Tonsilitis |
J03, J36 |
Vaccine preventable |
|
Neisseria meningitidis
|
A39 |
Haemophilus influenzae
|
G00.0, A41.3 |
Streptococcus pneumoniae
|
G00.1, A40.3 |
Measles |
B05 |
Mumps |
B26 |
Comorbidities
|
|
Asthma |
J45 |
Bronchopulmonary dysplasia |
P27.1 |
Extreme prematurity (<28 weeks) |
P07.2 (or ‘gestat’ 22-27 wks) |
Cystic fibrosis |
E84 |
Congenital cardiac disease |
Q20, Q21, Q24 |
Bronchiectasis |
J47 |
Immunodeficiency with predominantly antibody defects |
D80 |
Combined immunodeficiencies |
D81 |
Common variable immunodeficiency |
D83 |
Acute lymphoblastic leukaemia |
C91.0 |
Acute myeloid leukaemia |
C92.0 |
Covid-19
|
U07.1, U07.2 |